Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis

Lancet

Volumn 354, Issue 9178, 1999, Pages 569-570

  Boletis, John N ^a   Ioannidis, John P A ^c,d   Boki, Kyriaki A ^b   Moutsopoulos, Haralampos M ^b  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

^d TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033554258     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)01575-5     Document Type: Article

References (5)

1. Austin H.A. Jr., Klippel J.H., Balow J.E.et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 314:1986;614-619.
2. Boumpas D.T., Austin H.A., Vaughn E.M.et al. Risk of sustained amenorrhea in patients with severe lupus nephritis receiving pulse cyclophosphamide. Ann Intern Med. 119:1993;366-369.
3. Austin H.A. Jr., Boumpas D.T., Vaughn E.M., Balow J.E. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histological data. Kidney Int. 45:1994;544-560.
4. Corvetta A., Della Bitta R., Gabrielli A., Spaeth P.J., Danieli G. Use of high-dose intravenous immunoglobulin in systemic lupus erthyematosus: report of three cases. Clin Exp Rheumatol. 7:1989;295-299.
5. Winder A., Molad V., Osteld I., Kenet G., Pinkhas J., Sidi Y. Treatment of systemic lupus eryhthematosus by prolonged administration of high dose intravenous immunoglobulin: report of 2 cases. J Rheumatol. 20:1993;495-498.